reason report
lower estim reflect nt headwind gx advair track
pt
bottom line signific revenu ep guidanc
reduct disappoint impact durat
restructur morgantown facil remain unclear said
manag comment regard roadblock face
gain traction complex generics/biosimilar
margin surpris investor revis lower guidanc
believ number remaind look achiev
manag commentari around approv gener advair
year remain encourag reiter op rate lower
pt
chang model lower north america sale estim
repres y/i declin
bulk chang us gener relat morgantown
restructur littl visibl facil may
fulli oper much previou capac retain
declin carri outer year estim biosimilar
neulasta also temper uptak product model
vs previous vs
previous also lower spend outer year base
run-rat overal lower ep
ep
ebitda decreas yield lower pt
gx advair commentari posit approv still possibl
manag indic complet respons letter june
includ minor label chemistri manufactur control
relat question submit respons mid-juli
standard three month goal date although hope sinc product
prioriti design approv could come earlier manag
emphas addit data requir part respons
remain readi launch upon approv
ev/ebitda multipl
net debt total capit
gener
compani inform leerink partner llc research
revenu
pleas refer page import disclosur price chart analyst certif
morgantown restructur continu put pressur near-
term revenu margin long-term impact remain uncertain
expect on-going restructur remedi program
facil take rest complet manag
emphas disrupt product distribut facil
advers affect sale margin exit certain high
competit less profit product long term believ
bring back sustain level manag note addit
expens incur part restructur effort
addit takeaway acknowledg previou
strategi gx copaxon first nine month post-launch prove
ineffect signific list price reduct repres non-
tradit approach spur gener uptak manag note
may explor avenu drive uptak current effort
fail drive market share manag happi launch
far biosimilar neulasta first month partner
clinic payer particularli oncolog distributor group
purchas organ gpo model slow ramp
near-term biosimilar opportun includ insulin glargin
humira biosimilar eu note anticip suppli
constraint receiv gx restasi includ
minor question compani alreadi submit
respons although manag reiter expect
meaning financi contributor epipen suppli continu
variabl manag continu explor option restor
suppli manag continu expect high-single-digit growth
eu row region continu look complementari
bolt-on opportun manag look forward strateg
review help unlock valu provid addit detail given
earli natur process
place outperform rate share base strong pipelin biosimilar
durabl ou busi growth off-set continu us base busi
gener eros support revenu growth potenti near-term
upsid consensu number limit competit copaxon advair though
difficult high visibl insulin/biosimilar growth driver could
expand multipl rel peer strong balanc sheet allow
share buy-back smaller bolt-on acquisit expand geograph and/or therapeut
figur chang model
lp estim note number except ep margin
figur chang model continu
lp estim note number except ep margin
note number except ep margin
use weight averag ev/ebitda multipl ebitda deriv
price target per share
gener advair may get approv commerci uptak biosimilar may take longer
anticip growth ou market may slower expect market penetr
gener copaxon may improv biosimilar neulasta may slower estim
lp changevalu changevarianceconsensusactu vs consgeograph areanorth basic dilut non-gaap adjustmentstot one-tim net
number except per share data
net debt ebitda ratio
number except per share data
number except per share data
assum ftf product
gleevec approv launch
restasi assum launch pend approv
lialda launch jan zydu day exclus expir pend approv
advair assum get approv
cubicin assum get approv
ulor settlement june tent approv
treanda assum settlement par ftf date pend approv
norvir/kaletra assum patent expir jan tent approv
tarceva undisclos settlement assum month last patent approv
sutent lost feb patent tent approv
jevtana assum patent expiri pend approv
brilinta assum jul patent expiri pend approv
brevibloc undisclos settlement assum month last patent expiri approv
number except per share data
januvia franchis assum compound patent tent approv
vimpat lost patent expir pend approv
banzel settlement may approv
onglyza franchis lost jul patent pend approv
vyvans lost feb patent tent approv
assum ftf pipelin sub-tot
number except per share data
insulin collabor biocon
biosimilar collabor biocon momenta
herceptin approv launch
neulasta approv launch
eylea phase initi us patent protect
number except per share data
number except per share data
number except per share data
number except per share data
prepaid expens current
current portion ltd
number except per share data
adjust reconcil ni net cash oper
litig settlement conting net
loss acquisition-rel foreign currenc deriv
loss equiti method invest
write financ fee
decreas increas work capit
paid acquisit net
purchas properti plant equip capital-expenditure
payment product right net
paid meda uncondit defer payment
settlement acquisition-rel foreign currenc deriv
proce sale asset subsidiari
purchas market secur
chang restrict cash
proce sale market securitin
net invest
payment financ fee
proce convert note hedg
proce issuance/ purchas ordinari share net
proce exercis stock option
tax paid relat net share settlement equiti award
acquisit non-controlling interest
net financ
effect cash chang exchang rate
net chang equival
